Breaking the Central Dogma

When Francis Crick articulated the "central dogma" of molecular biology in 1958, the flow of genetic information seemed clear: DNA → RNA → Protein. DNA was the master copy, RNA the messenger, protein the functional product. Information flowed one way.

Retroviruses break this rule. They carry their genetic information as RNA, then use a remarkable enzyme called reverse transcriptase to convert that RNA into DNA, reversing the presumed flow of genetic information. This DNA copy then integrates permanently into the host cell's chromosomes.[1]

The discovery of reverse transcriptase in 1970 by Howard Temin and David Baltimore (independently) earned them the Nobel Prize and revolutionized our understanding of molecular biology.

Anatomy of a Retrovirus

Retroviruses share a common structure:

Retroviral Components
  • Envelope: Lipid membrane stolen from host cell, studded with viral glycoproteins for cell entry
  • Matrix: Protein layer beneath the envelope
  • Capsid: Protein shell protecting the genome
  • Genome: Two copies of single-stranded RNA (diploid)
  • Enzymes: Reverse transcriptase, integrase, protease (packaged inside the virion)

The genome contains three essential genes:

Complex retroviruses like HIV carry additional regulatory and accessory genes that modulate replication and evade immune responses.

The Replication Cycle

Retroviral replication is an elegant process:[2]

1. Attachment and Entry

Envelope glycoproteins bind specific receptors on target cells. For HIV, this is CD4 plus a coreceptor (CCR5 or CXCR4). Binding triggers membrane fusion, releasing the viral core into the cytoplasm.

2. Reverse Transcription

Inside the cytoplasm, reverse transcriptase performs its signature trick. The enzyme has three activities:

The result is double-stranded DNA (called the provirus) flanked by long terminal repeats (LTRs) that contain regulatory sequences.

3. Nuclear Import and Integration

The proviral DNA, complexed with viral and cellular proteins, enters the nucleus. The viral integrase enzyme then catalyzes integration: cutting the host DNA and inserting the provirus. This step is irreversible; the viral DNA becomes a permanent part of the cell's genome.

4. Transcription and Translation

The integrated provirus is now transcribed by host RNA polymerase II, just like any cellular gene. Viral RNA serves both as mRNA for protein synthesis and as genomic RNA to be packaged into new virions.

5. Assembly and Budding

Viral proteins and genomic RNA assemble at the cell membrane. New virions bud off, acquiring their envelope. The viral protease cleaves precursor proteins into mature forms, generating infectious particles.

HIV: The Most Studied Retrovirus

Human Immunodeficiency Virus (HIV) infects CD4+ T cells, the conductors of the immune orchestra. As these cells are destroyed, the immune system collapses, leading to AIDS (Acquired Immunodeficiency Syndrome).

HIV's complexity exceeds simple retroviruses. Beyond gag, pol, and env, it carries:[3]

HTLV: The Cancer-Causing Retrovirus

Human T-lymphotropic Virus (HTLV) takes a different path than HIV. Rather than killing T cells, HTLV-1 causes them to proliferate uncontrollably, potentially leading to Adult T-cell Leukemia/Lymphoma (ATL), a cancer of T cells.[4]

Key differences from HIV:

The Tax protein of HTLV-1 is the key oncogenic driver, promoting cell proliferation and genomic instability.

Antiretroviral Therapy

Understanding retroviral replication enabled targeted drug development. Modern antiretroviral therapy (ART) attacks multiple steps:[5]

Antiretroviral Drug Classes
  • Entry inhibitors: Block attachment or fusion (maraviroc, enfuvirtide)
  • NRTIs: Nucleoside RT inhibitors, which are faulty building blocks that terminate DNA synthesis (zidovudine, tenofovir)
  • NNRTIs: Non-nucleoside RT inhibitors, which bind and disable RT (efavirenz, rilpivirine)
  • Integrase inhibitors: Block proviral integration (dolutegravir, bictegravir)
  • Protease inhibitors: Prevent maturation of viral proteins (darunavir, atazanavir)

Combination therapy (typically 3 drugs from 2+ classes) has transformed HIV from a death sentence to a manageable chronic condition. People on effective ART have near-normal life expectancy and cannot transmit the virus (U=U: Undetectable = Untransmittable).

Endogenous Retroviruses: Our Ancient Viral Heritage

Perhaps the most remarkable retroviral story is written in our own DNA. About 8% of the human genome consists of endogenous retroviruses (ERVs): remnants of ancient retroviral infections that infected germ cells and were passed to offspring.[6]

Most ERVs accumulated mutations over millions of years and can no longer produce infectious virus. They're molecular fossils, recording infections that occurred throughout primate evolution.

But some ERVs have been co-opted for host functions:

"We are, in a very real sense, part virus. Ancient retroviruses shaped our genome and contributed functions we now depend on for survival."

Retroviruses as Tools

The same properties that make retroviruses dangerous also make them useful:

The ability to stably integrate genes into chromosomes (once a terrifying feature) becomes a benefit when harnessed for therapy.

The Ongoing Battle

Despite ART's success, HIV remains incurable. The integrated provirus hides in long-lived reservoir cells, invisible to the immune system and unaffected by drugs. Stopping therapy allows the virus to rebound from these reservoirs.

Current research pursues:

Retroviruses challenged our understanding of molecular biology and taught us that genetic information can flow backward. They've caused devastating epidemics and left indelible marks on our genome. Understanding them has led to life-saving therapies and powerful research tools. In the ongoing dialogue between viruses and hosts, retroviruses have proven to be among the most formidable, and most instructive, adversaries.

Sources

  1. Coffin, J. M., Hughes, S. H., & Varmus, H. E. (1997). Retroviruses. Cold Spring Harbor Laboratory Press.
  2. Hu, W. S., & Hughes, S. H. (2012). HIV-1 reverse transcription. Cold Spring Harbor Perspectives in Medicine, 2(10).
  3. Freed, E. O. (2015). HIV-1 assembly, release and maturation. Nature Reviews Microbiology, 13(8), 484-496.
  4. Gessain, A., & Cassar, O. (2012). Epidemiological aspects and world distribution of HTLV-1 infection. Frontiers in Microbiology, 3, 388.
  5. Arts, E. J., & Hazuda, D. J. (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine, 2(4).
  6. Feschotte, C., & Gilbert, C. (2012). Endogenous viruses: insights into viral evolution and impact on host biology. Nature Reviews Genetics, 13(4), 283-296.